|
23 Nov 2020 |
ImmunityBio Announces Publication of Preclinical Data Demonstrating IL-15 Superagonist N-803 Improves Natural Killer-Mediated Tumor Cell Killing
|
|
23 Nov 2020 |
Molecular Partners Doses First Cohort in Phase 1 Trial of COVID-19 DARPin® Therapeutic Candidate MP0420
|
|
18 Nov 2020 |
FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe disease
|
|
17 Nov 2020 |
Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)
|
|
17 Nov 2020 |
Once-weekly semaglutide 2.0 mg demonstrates superior reduction in HbA1c vs once-weekly semaglutide 1.0 mg in people with type 2 diabetes in the SUSTAIN FORTE trial
|
|
17 Nov 2020 |
Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNH
|
|
16 Nov 2020 |
Genenta’s Temferon™: Evidence of Controlled and Targeted Interferon Expression in Preliminary Phase I/II Clinical Data in Glioblastoma Multiforme
|
|
16 Nov 2020 |
Gilead and Novo Nordisk present new data from proof-of-concept trial in NASH
|
|
15 Nov 2020 |
Data from SG016 Phase II Clinical Trial published in Lancet Respiratory Medicine
|
|
13 Nov 2020 |
Gemini Therapeutics Announces GEM103 Meets All Endpoints in Phase 1 Clinical Study
|
|
13 Nov 2020 |
Axcella Presents Data for AXA1125 at The Liver Meeting® 2020
|
|
13 Nov 2020 |
AM-Pharma Announces Enrollment of the First Patient in REVIVAL Phase III Pivotal Trial in Patients with Sepsis-Associated Acute Kidney Injury
|
|
13 Nov 2020 |
Xilio Therapeutics Presents Promising Preclinical Tumor-Selective Efficacy and Safety Data for XTX201 (IL-2) and XTX101 (anti-CTLA-4) at SITC
|
|
12 Nov 2020 |
amcure and Hinova Pharmaceuticals enter into an exclusive license agreement for the development, manufacturing and commercialization of AMC303 in oncology in the Greater China region
|
|
11 Nov 2020 |
SOTIO Presents Interim Data from its Phase 1/1b Study of SO-C101 in Patients with Advanced Solid Tumors at SITC 2020
|
|
10 Nov 2020 |
Medikine to Present Breakthrough Discoveries of Peptide-Based Agonists of IL-7 and IL-2/15 Receptors at SITC 2020
|
|
10 Nov 2020 |
Revance Announces Results of Phase 2 Trial of DaxibotulinumtoxinA for Injection in Plantar Fasciitis
|
|
09 Nov 2020 |
OncoNano Announces Positive Preclinical Data for ONM-400 Tumor Specific IL-2 Delivery at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
|
|
09 Nov 2020 |
Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting
|
|
05 Nov 2020 |
New Clinical Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at 2020 American College of Rheumatology (ACR) Congress
|
|
03 Nov 2020 |
Higher Response Rates in RECIPE Randomized Controlled Trial of KRYSTEXXA® (pegloticase injection) Concomitantly Used with the Immunomodulator Mycophenolate Mofetil
|
|
03 Nov 2020 |
Aurinia Announces Outcome of AUDREY™ Clinical Trial in Dry Eye Syndrome
|
|
02 Nov 2020 |
Neuraly Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 2B Trial of NLY01 for Patients with Alzheimer’s Disease
|
|
30 Oct 2020 |
Protagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in Collaboration with Janssen
|
|
29 Oct 2020 |
Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab) in pursuit of establishing a new treatment option in oncology
|
